Sinopharm Group Co. Ltd.
SHTDY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.01 | -0.46 | -0.16 | 0.14 |
| FCF Yield | -66.73% | 82.87% | -70.28% | 102.64% |
| EV / EBITDA | 9.89 | 7.86 | 12.33 | 5.02 |
| Quality | ||||
| ROIC | 2.34% | 2.72% | 2.80% | 3.99% |
| Gross Margin | 7.26% | 7.70% | 7.45% | 8.54% |
| Cash Conversion Ratio | -9.87 | 15.70 | -11.07 | 12.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.87% | 10.24% | 8.58% | 9.25% |
| Free Cash Flow Growth | -168.06% | 221.62% | -170.90% | 234.54% |
| Safety | ||||
| Net Debt / EBITDA | 4.64 | 2.07 | 6.06 | 0.74 |
| Interest Coverage | 15.62 | 7.00 | 8.52 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 4.05 | 4.29 | 3.96 | 4.50 |
| Cash Conversion Cycle | 47.24 | 32.40 | 45.32 | 25.03 |